Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.59 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.59 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.55 |
| ▸ | PREP | P48147 | 3/20 | 0.51 |
| ▸ | FAP | Q12884 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3818215 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP7DPP9PREP | |
| SCHEMBL3812156 | 0.88 | DPP4 (0.78) | DPP4DPP8DPP7DPP9PREP | |
| SCHEMBL3812162 | 0.88 | DPP4 (0.78) | DPP4DPP8DPP7DPP9PREP | |
| SCHEMBL4593899 | 0.82 | DPP4 (0.70) | DPP4DPP8DPP7 | |
| SCHEMBL664217 | 0.82 | DPP4 (0.70) | DPP4DPP8DPP7 | |
| Hydrochloric Acid SCHEMBL6701343 | 0.81 | DPP4 (0.69) | DPP4DPP8DPP7 | |
| SCHEMBL663691 | 0.80 | DPP4 (0.67) | DPP4DPP8DPP7DPP9 | |
| SCHEMBL4594622 | 0.80 | DPP4 (0.67) | DPP4DPP8DPP7DPP9 | |
| Hydrochloric Acid SCHEMBL3195551 | 0.76 | DPP4 (0.97) | DPP4DPP8DPP9 | |
| Hydrochloric Acid SCHEMBL3195546 | 0.76 | DPP4 (0.97) | DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296974-B1 | 2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2009-08-05 | — | — | EP | disclosed |
| EP-1296974-A2 | 2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2003-04-02 | — | — | EP | disclosed |
| US-20020193390-A1 | Pharmaceutical compositions containing an N-(substituted glycyl)-2- cyanopyrrolidine and at least one other antidiabetic agent and their use in inhibiting dipeptidyl peptidase-IV | VILLHAUER EDWIN BERNARD (US) | 2002-12-19 | — | — | US | disclosed |
| US-6432969-B1 | NON-INSULIN DEPENDENT DIABETES, OBESITY, ARTHRITIS, AND OSTEOPOROSIS TREATMENT | NOVARTIS AG (CH) | 2002-08-13 | — | — | US | disclosed |
| WO-2001096295-A2 | 2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193390-A1 | Pharmaceutical compositions containing an N-(substituted glycyl)-2- cyanopyrrolidine and at least one other antidiabetic agent and their use in inhibiting dipeptidyl peptidase-IV | DPP4, DPP9, DPP7 | DPP4 1/4885DPP8 6/4885DPP7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.